Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 809Precursor Cell Lymphoblastic Leukemia-Lymphoma 171Recurrence 141Neoplasms, Plasma Cell 111Lymphoma 93Leukemia 91Neoplasms 81Burkitt Lymphoma 57Vomiting 51Lymphoma, Non-Hodgkin 50Immunoglobulin Light-chain Amyloidosis 50Lymphoma, Large B-Cell, Diffuse 44Nausea 38Lymphoma, Mantle-Cell 38Prostatic Neoplasms 31Lymphoma, Follicular 30Hodgkin Disease 29Waldenstrom Macroglobulinemia 27Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 27Neoplasm Metastasis 26Leukemia, Lymphocytic, Chronic, B-Cell 26Carcinoma, Non-Small-Cell Lung 26Leukemia, Myeloid, Acute 25Breast Neoplasms 25Lung Neoplasms 23Amyloidosis 21Leukemia, Biphenotypic, Acute 18Lymphoma, B-Cell, Marginal Zone 17Lymphoma, Extranodal NK-T-Cell 16Smoldering Multiple Myeloma 15

Interventions

Carboplatin 8Trastuzumab 6Docetaxel 5pembrolizumab 4Paclitaxel 4Oxaliplatin 4Fluorouracil 4Cytarabine 4Cyclophosphamide 4Azacitidine 4pertuzumab 3Radiotherapy 3Observation 3Neoadjuvant Therapy 3Epirubicin 3Endoscopy 3Cisplatin 3Chemoradiotherapy 3Capecitabine 3130-nm albumin-bound paclitaxel 3venetoclax 2toripalimab 2sargramostim 2olaparib 2durvalumab 2cc-486 2Tretinoin 2Surgical Procedures, Operative 2Standard of Care 2Pemetrexed 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pathologic Complete Response × Dexamethasone × Clear all
NCT01134484 2012-07-20

VELCADE-Thalidomide-Dexamethasone (VTD) vs Thalidomide-Dexamethasone (TD) Incorporated Into Double Autotransplantation for Untreated Multiple Myeloma (MM)

IRCCS Azienda Ospedaliero-Universitaria di Bologna

Phase 3 Unknown
480 enrolled
Plasma cell

Pathologic Complete Response, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡